BioRad Laboratories and Xellar Collaborate to Transform Preclinical Research with Advanced Technologies
- Xellar Biosystems collaborates with WOOJUNG BIO to enhance preclinical research using AI and organ-on-a-chip technology.
- The partnership aims to improve drug discovery efficiency, data quality, and reproducibility in life sciences research.
- Xellar's 3D human tissue models offer a modern approach to drug testing, addressing real-world research needs.
Forging New Frontiers in Preclinical Research: The Xellar and WOOJUNG BIO Collaboration
In a significant development for the life sciences sector, Xellar Biosystems has embarked on a multi-year strategic collaboration with South Korea’s WOOJUNG BIO Co., Ltd. This partnership aims to leverage Xellar's cutting-edge AI and computer vision-assisted organ-on-a-chip technology alongside WOOJUNG BIO’s extensive translational research capabilities. The combination of these innovative approaches is set to enhance preclinical research solutions, focusing on improving the efficiency, data quality, and reproducibility of drug discovery and safety evaluations.
Xellar, established in 2022, specializes in creating realistic 3D human tissue models that can significantly streamline drug testing and toxicity assessments compared to traditional methodologies. By integrating WOOJUNG BIO’s translational research expertise, the collaboration seeks to address pressing real-world research needs. Xin Xie, CEO of Xellar, emphasizes that this partnership represents a pivotal moment in applying their advanced technologies to meet the evolving demands of the life sciences community. The integration of their joint workflows and technologies is expected to foster breakthroughs that will enhance both the speed and reliability of preclinical research.
Heejung Chun, CEO of WOOJUNG BIO, points out the increasing necessity for human-relevant preclinical research approaches. The partnership not only aims to strengthen the capabilities of both companies but also to support the broader landscape of life sciences research. As the industry moves towards more sophisticated and predictive research methods, this collaboration underscores a commitment to advancing preclinical methodologies that can lead to more effective therapeutic solutions. By combining their strengths, Xellar and WOOJUNG BIO aim to pioneer next-generation research tools that promise to reshape drug discovery and development processes.
In related industry news, ProGro BIO has announced compelling findings from a third-party study indicating that its microbial soil inoculant, Rhizol®, significantly enhances soil health and crop nutrition. Conducted by the North Carolina Department of Agriculture & Consumer Services, the study analyzed over 1,000 soil samples and revealed that Rhizol® improves nutrient retention and soil strength, validating the positive experiences reported by farmers.
Zach Lancaster, ProGro BIO’s Director of Field Agronomy & Grower Relations, highlights the practical value of Rhizol® in optimizing agricultural practices. The research demonstrates a marked improvement in the retention of essential nutrients such as phosphorus, potassium, and sulfur in treated soils, marking a promising step for farmers seeking to enhance yield while maintaining soil health. This ongoing evolution in agricultural technology parallels the advancements being made in the life sciences sector, reflecting a broader trend towards innovative solutions in both fields.